Correction offers good value in pharma stocks

correction offers good value in pharma stocks The U.S. subsidiary, Taro (a fourth of sales), the heat in the June quarter due to increased competiti...


correction offers good value in pharma stocks
The U.S. subsidiary, Taro (a fourth of sales), the heat in the June quarter due to increased competition in key dermatology products such as nystatin triamcinolone (about 12 percent of the revenue Taro) felt, recovered in the September quarter.
more Read on

Leave a Reply